| Pharmaks Agency |
| E enjte, 19 Gusht 2004 21:11 | ||
|
Small Company – Smart Solutions PHARMAKS is Agency for publication, marketing, counselling and regulatory affairs for Kosova medicine, medical device and food supplement market. PHARMAKS is dealing in Marketing Authorization Application according to national and EU regulatory requirements and procedures (medicinal products) or registrations (herbal medicinal products and food supplements) and notification or certification processes (medical devices). We are also producing Summary Product Characteristics and Patient Information Leaflets of medicines according to national and EU rules. PHARMAKS professional team includes highly experienced pharmacists, physicians and health related professionals. PHARMAKS is leading agency in Kosova for professional translation in the fields of pharmaceuticals and medicine. More than 20 world known pharmaceutical companies were our clients: Sanofi-Aventis, Sanofi-Pasteur, Hoffmann La Roche, Boehringer Ingelheim, Bayer, AstraZeneca, Abbot Laboratories, Abbot, Dr. Falk Pharma, Johnson & Johnson, Jansen-Cilag, Nycomed, Engelhard, Natural Wealth, Bosnalijek, Jadran Galenski Laboratorij, Hemofarm, Novit Pharm, Actavis, Merck KGaA, Merck Serono, Berlin Chemie - Menarini Group, Solvay Pharma, Nivea, etc. PHARMAKS was first to translate from English into Albanian Glossary of pharmaceutical forms of EDQM. Reliability, accuracy, trustfulness and professionalism are our added values in relations with our clients. Portfolio of PHARMAKS:
PharmINDEX 2009 – was the bestselling pharmaceutical and medicinal book in Republic of Kosova in 2009. Our website www.pharmaks.com is most visited portal for pharmacy and medicine in Albanian language. PHARMAKS is agency you can ever trust.
Address: Ulpiana D9/3/2 Prishtinë Republic of Kosova Phone/fax: +381 38 55 11 47 mobile phone: +377 44 166 590, +377 44 138 254, +386 49 166 590, + 386 49 138 254 email: Ky email po mbrohet prej spambots-ave, të duhet JavaScript me e pa , Ky email po mbrohet prej spambots-ave, të duhet JavaScript me e pa , Ky email po mbrohet prej spambots-ave, të duhet JavaScript me e pa website: www.pharmaks.org
|
FDA ka njoftuar profesionistët shëndetësor për një studim të ri duke raportuar një rritje të vogël në vdekje kardiovaskulare dhe në rrezik nga vdekja nga çfarëdo shkaktari, në pacientët e trajtuar me një kurs 5 ditor me azitromicin (Zithromax; Pfizer) krahasuar me personat e trajtuar me amoksicilin, ciprofloksacin ose pa barna.
